AT-301 was under investigation in clinical trial NCT01675284 to evaluate the safety, reactogenicity, and humoral immune responses to an inactivated H5N1 influenza vaccine.
- Mechanism
- Curator reviewed
AT-301 is a proprietary nasal formula developed by Atossa intended for administration in patients diagnosed with COVID-19 who do not have symptoms severe enough for hospitalization. This formulation aims to prevent infection by potentially interfering with spike protein activation through host proteases, by masking receptor binding domains, and by providing a generalized mucoadhesive epithelial barrier to block the entry of the SARS-CoV-2 viral gene proteins in the nasal epithelial cells. AT-301 is currently being investigated against COVID-19.
- Code names
- AT-301
What you can answer from here — as of July 13, 2024
Which companies are running trials of AT-301, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account